1. Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. (1st October 2019) Authors: Marmorino, F; Rossini, D; Lonardi, S; Moretto, R; Zucchelli, G; Aprile, G; Dell'Aquila, E; Ratti, M; Bergamo, F; Masi, G; Urbano, F; Ronzoni, M; Libertini, M; Borelli, B; Randon, G; Buonadonna, A; Allegrini, G; Pella, N; Ricci, V; Boccaccino, A Journal: Annals of oncology Issue: Volume 30:Number 12(2019) Page Start: 1969 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. O-007Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)+irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cet+iri: Final results and translational analyses of the CRICKET study by GONO. (20th June 2018) Authors: Rossini, D; Cremolini, C; Conca, E; Del Re, M; Busico, A; Pietrantonio, F; Bergamo, F; Danesi, R; Cardellino, G; Tamburini, E; Dell'Aquila, E; Strippoli, A; Masi, G; Tonini, G; Negri, F; Corsi, D; Pella, N; Intini, R; Falcone, A; Santini, D Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. O-013Impact of age and gender on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: a pooled analysis of TRIBE and TRIBE2 studies. (2nd July 2019) Authors: Zucchelli, G; Marmorino, F; Rossini, D; Aprile, G; Casagrande, M; Lonardi, S; Murgioni, S; Dell'Aquila, E; Tomasello, G; Moretto, R; Antoniotti, C; Borelli, B; Urbano, F; Ronzoni, M; Zaniboni, A; Manglaviti, S; Buonadonna, A; Ritorto, G; Masi, G; Allegrini, G Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. O-017FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in mCRC: Final results of the phase II randomized MOMA trial by GONO. (20th June 2018) Authors: Marmorino, F; Cremolini, C; Bergamo, F; Pella, N; Antoniotti, C; Rossini, D; Dell'Aquila, E; Masi, G; Salvatore, L; Loupakis, F; Marcucci, L; Gemma, D; Cardellino, G; Borelli, B; Ricci, V; Delfanti, S; Mori, E; Tonini, G; Lonardi, S; Fontanini, G Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. O-017FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in mCRC: Final results of the phase II randomized MOMA trial by GONO. (20th June 2018) Authors: Marmorino, F; Cremolini, C; Bergamo, F; Pella, N; Antoniotti, C; Rossini, D; Dell'Aquila, E; Masi, G; Salvatore, L; Loupakis, F; Marcucci, L; Gemma, D; Cardellino, G; Borelli, B; Ricci, V; Delfanti, S; Mori, E; Tonini, G; Lonardi, S; Fontanini, G Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P-101A real-life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second-line therapy. (2nd July 2019) Authors: Parisi, A; Cortellini, A; Roberto, M; Venditti, O; Santini, D; Dell'Aquila, E; Stellato, M; Marchetti, P; Occhipinti, M; Zoratto, F; Mazzuca, F; Tinari, N; De Tursi, M; Iezzi, L; Natoli, C; Ratti, M; Pizzo, C; Ghidini, M; Ficorella, C; Cannita, K Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P-237Development of a new clinical nomogram including velocity rate of disease progression to predict outcome in metastatic colorectal cancer patients treated with bevacizumab beyond progression: A subanalysis from tribe trial. (20th June 2018) Authors: Dell'Aquila, E; Pantano, F; Rossini, D; Stellato, M; Lonardi, S; Masi, G; Schirripa, M; Marmorino, F; Antoniotti, C; Murgioni, S; Tomasello, G; Ronzoni, M; Racca, P; Vincenzi, B; Allegrini, G; Urbano, F; Buonadonna, A; Banzi, M; Tonini, G; Cremolini, C Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P-237Development of a new clinical nomogram including velocity rate of disease progression to predict outcome in metastatic colorectal cancer patients treated with bevacizumab beyond progression: A subanalysis from tribe trial. (20th June 2018) Authors: Dell'Aquila, E; Pantano, F; Rossini, D; Stellato, M; Lonardi, S; Masi, G; Schirripa, M; Marmorino, F; Antoniotti, C; Murgioni, S; Tomasello, G; Ronzoni, M; Racca, P; Vincenzi, B; Allegrini, G; Urbano, F; Buonadonna, A; Banzi, M; Tonini, G; Cremolini, C Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. PD-027Efficacy of retreatment with anti-EGFRs in metastatic colorectal cancer is not predictable by clinical factors related to prior lines of therapy: a multi-institutional analysis. (2nd July 2019) Authors: Rossini, D; Pagani, F; Pellino, A; Dell'Aquila, E; Liscia, N; Bensi, M; Germani, M; Masi, G; Moretto, R; Santini, D; Salvatore, L; Scartozzi, M; Lonardi, S; Zucchelli, G; Puglisi, F; Vannini, F; Colombo, C; Falcone, A; Pietrantonio, F; Cremolini, C Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗